Trial Profile
PHASE II STUDY OF BAY 43-9006 IN PATIENTS WITH ADVANCED CHOLANGIOCELLULAR CARCINOMA.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2014
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Cholangiocarcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms SORACCC
- 31 May 2011 New trial record